Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers

ISNES, Belgium, Aug. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced a three-year agreement to work with the renowned expert Professor Stefan Holdenrieder at the Institute of Laboratory Medicine of the German Heart Center at the Technical University of Munich, Germany.

Volition's Chief Executive Officer, Cameron Reynolds, commented, "I am delighted we are working with Professor Holdenrieder at his new laboratory in Munich. As a leading expert in the field of nucleosomics, he will support our analytical and preanalytical research and assist our efforts to secure large trials in a range of cancers - including lung, pancreatic, prostate, colorectal, breast and ovarian."

Professor Holdenrieder is the Director of the Institute of Laboratory Medicine and will be the principal investigator on Volition's nucleosome projects, aided by several members of his team. Professor Holdenrieder is an expert in the field of circulating nucleosomes and is widely published. He currently serves as Secretary of the International Society of Oncological BioMarkers, External Quality Assessment consultant for tumor marker ring trials at INSTAND e.V. and Associate Editor of several international scientific journals.

"My main research focus is the development and evaluation of new biomarkers that are useful in cardiology, oncology and immunology. Blood-based biomarkers such as Volition's Nu.Q assays are involved in all of these important medical fields. Nucleosomes are involved in thrombogenesis, in immune reaction and have the potential to help in the detection and management of cancer," commented Professor Holdenrieder.

The Institute has a Biomarker Center for the validation of new technologies and has expertise in the methodical, preanalytical and analytical evaluation of new biomarkers that may be useful for disease detection and patient management. It also owns and operates a biobank of biological samples taken from a large cohort of individuals in particular, those with diverse cardiovascular diseases.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx

LinkedIn: https://www.linkedin.com/company/volitionrx  

Facebook: https://www.facebook.com/VolitionRx/

YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition


+44 (0)7557 774620

Scott Powell, Volition


+1 (646) 650 1351

Tirth Patel, Edison Advisors


+1 (646) 653 7035

Rachel Carroll, Edison Advisors


+44 (0)20 3077 5711

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

View original content:http://www.prnewswire.com/news-releases/volition-signs-agreement-with-the-institute-of-laboratory-medicine-of-the-technical-university-of-munich-germany-to-assist-in-securing-large-trials-in-a-range-of-cancers-300507737.html

SOURCE VolitionRx Ltd